XIX International AIDS Conference

SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves serum lipids in HIV-1-positive subjects TUAB0104

Time: 11:50
Speaker: Frank Palella

This text willreplaced

You can download the video file here

For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.

Contact Us | Site map © 2012 International AIDS Society